Probiodrug, a Germany-based biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD) and other neurodegenerative disorders, has reported that Last Patient’s Last Visit (LPLV) occurred on 05 April 2017 in the currently running Phase 2a SAPHIR study investigating the QC-inhibitor PQ912 in patients with early AD.
The study randomized 120 patients in seven countries at 21 investigational sites, the company said in its press release on Friday.
Key results for the primary endpoint of safety/tolerability and for components of the three exploratory endpoints – cognition, EEG/fMRI and the main molecular biomarkers are expected to be communicated in early June 2017 and other, additional information will be available later in the year.
Commenting on the announcement, Dr Inge Lues, CDO of Probiodrug said: It will be extremely exciting to see the results of the very innovative differentiated approach of QC inhibition, evaluated in early AD-patients applying very innovative trial design, which will provide instrumental information to further pursue the concept with our drug candidate PQ912.”